Efficacy and Safety of Temozolomide for the Treatment of Advanced or Recurrent Ependymoma: A Meta-Analysis

Key Points

• Temozolomide shows significant efficacy in treating advanced ependymoma, particularly in recurrent cases.
• The meta-analysis indicates an overall response rate of approximately 30% in patients treated with temozolomide.
• Observational analysis across multiple studies reveals that temozolomide is generally well-tolerated with manageable adverse effects.
• Findings suggest that temozolomide may provide a valuable treatment option, but further studies are warranted to confirm long-term outcomes.